1. Home
  2. ACR vs IKT Comparison

ACR vs IKT Comparison

Compare ACR & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ACR

ACRES Commercial Realty Corp.

HOLD

Current Price

$23.75

Market Cap

143.3M

Sector

Real Estate

ML Signal

HOLD

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$1.54

Market Cap

181.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACR
IKT
Founded
2005
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
143.3M
181.9M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
ACR
IKT
Price
$23.75
$1.54
Analyst Decision
Buy
Buy
Analyst Count
2
2
Target Price
$24.50
$4.00
AVG Volume (30 Days)
49.9K
411.5K
Earning Date
10-29-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
14.65
N/A
EPS
0.95
N/A
Revenue
$88,952,000.00
N/A
Revenue This Year
$4.05
N/A
Revenue Next Year
$0.38
N/A
P/E Ratio
$25.11
N/A
Revenue Growth
14.87
N/A
52 Week Low
$14.94
$1.33
52 Week High
$24.17
$4.20

Technical Indicators

Market Signals
Indicator
ACR
IKT
Relative Strength Index (RSI) 70.16 53.05
Support Level $22.74 $1.43
Resistance Level $24.17 $1.57
Average True Range (ATR) 0.91 0.10
MACD 0.23 0.01
Stochastic Oscillator 94.16 73.81

Price Performance

Historical Comparison
ACR
IKT

About ACR ACRES Commercial Realty Corp.

ACRES Commercial Realty Corp is a commercial real estate investment trust that focuses on originating, holding and managing commercial real estate (CRE) mortgage loans and equity investments in commercial real estate properties through direct ownership and joint ventures. The company invests in commercial real-estate-related assets, including whole loans, A notes, B notes, mezzanine loans, and mortgage-related securities, as well as commercial finance assets, which include other asset-backed securities, senior secured corporate loans, equipment leases and notes, trust preferred securities, debt tranches of collateralize debt obligations, and private equity investments mainly issued by financial institutions.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

Share on Social Networks: